{"name":"ReNetX Bio, Inc.","slug":"renetx-bio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AXER-204","genericName":"AXER-204","slug":"axer-204","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AXER-204","genericName":"AXER-204","slug":"axer-204","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPNWw2SC1fc2EzUnlmeGotaWJ2MkNfempIZllBc1l6RmUtMWFNZjdRS2praVFDZnFPSnhMS09OQ0JvNUtDVUNUZWs5MlFWUk1aeVRkZVY1ZG9wM1VsWEt6THpPMEFYdGdIakpzUjRxSlV5b3lsc3BTLU8xbHAwajNLOWRRRi1VWVlKelMyVWFMb205clU?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Segmentation, Major Trends, and Competitive Overview of the Acute Spinal Cord Injury Market - openPR.com","headline":"Segmentation, Major Trends, and Competitive Overview of the Acute Spinal Cord Injury Market","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-02","type":"pipeline","source":"The Manila Times","summary":"The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight - The Manila Times","headline":"The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxOZWhKWGJZb0MwXzhKMENORnU5X0V0OE9DODhiWjJxcXpuLVBiaV94NFZZUHl3eWRLLWNtT0VhVlB3MTFwMDVpczVLdE4ySnVfMHpoeTZaeDBZclVvZTVkd3ZHbEU2Vi0zc3l6WmE5S1hGRFNKeG1kUFN5cl9DeWFBNDRxaHhjLVZaXzlJTGVxaEhCV0ZDeGlIS0RpYzBLN2dPZXRvQlQ4RmdRSmk5aXIzRm15STJYOVEwak5fV2hBN25RRVk2NG15NVQ5eE0yVmp0OWxpd2g3bmJyekwxT1BlTnVNb0tKeU03MnZZQi0zdDdUcnpvOUF0c2s4dUxYTVlLYm1JTmVOR3NUOXBFX2UteFp3SHZHdGlnTGpGbnhzUzZVM0NPY2RNWGVKRUVvWEVDa2JRaUNXZHJXRVhhU2MyLTN1dnBFdjI1WkVNMVQtOFBPaDg?oc=5","date":"2026-03-30","type":"regulatory","source":"Barchart.com","summary":"Spinal Cord Injury Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development, Kessler - ","headline":"Spinal Cord Injury Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsig","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxOT1hqa1FCMUFueTVQdVFpZzJVVGU0eHdEbW1aUVNabDd5TlhSNGs1ck9BRDR3T2dXemotelpZNG1uRE9QQklHbU5FV1JZUFpQV1gyem45X3FxLXNNU0FJWEtOaGM5NUN2R0ZNNTU1SWs4RXU1TmpJbFBOQ1BfeE93a0dGdHluZWFCMWFnOGVfZk95S0ZRV1E1TDU0NFlWaEE5UzJDN1FkSjJQWmRmZzhEX1dpa2VrZ19qUkd6V3BTcFdOZEZxM2JNbW9tRWY3SWNJSG5iaEsxeGpLLXlMZGFCS04xTGktOHZfdEE3TXROZkk2YWNhcHNNYWdGdmMtaXVXaUozdzhMY3NMY3BBaVZBUTl1SzZNWWtWa1NteGJCTDFZQThqV2xqWUJDOXhKdjVBVENRcjdZakc5WVVWM3JYMEo5ZnA?oc=5","date":"2025-02-19","type":"pipeline","source":"PR Newswire UK","summary":"Spinal Cord Injury Drug Treatment Market is Predicted to Reach New Heights with the Anticipated Launch of Emerging Therapies and Breakthroughs by 2034 | DelveInsight - PR Newswire UK","headline":"Spinal Cord Injury Drug Treatment Market is Predicted to Reach New Heights with the Anticipated Launch of Emerging Thera","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxPUl9Oc0ZfTDFrV1F0Q2RmUGx4aTM1ZlJtdDAwVFBKZTRXSUJhMUc4WUZpVmxTN3JrZkc1bVN5RGdtaHFJS21pOVUzWlFvRFBhMGtLNExhWEZZS2tnVlotdHRVTUhjWFZ3MDd4S2w0UnF0ZVpqS2hXZXVZRkYyRUxBTHlTYnZ2Q2lqbHMwdFFvVk5oNXJjWW9keFROTmRhQ1VnX1l6OWlCSW1VNWJpcTY2X05qRXNSSk9ISDNMdlNVUUZQMDc3RXBXcm8yUU5RUmVGZWJ2MDQ2dEVnZDRKbVp1Z1AzazhBWkgxMW9sZXBuTl9IXzhqT1pkS0dKYW9JUjlCTWc?oc=5","date":"2024-01-31","type":"pipeline","source":"PR Newswire UK","summary":"Spinal Cord Injury Therapeutics Market surpass $10.7 billion by 2031 - Exclusive Report by Coherent Market Insights - PR Newswire UK","headline":"Spinal Cord Injury Therapeutics Market surpass $10.7 billion by 2031 - Exclusive Report by Coherent Market Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFBqeG1GVkZuRUtTSHZ6Ny1GdThMNFNDZjRlcklsWmh0NTIzNHdjVUdCOVlzX0d3MG9BaWZuN29SV2Z4YW5XOG1Xb3hTTjZlRDQ3Ymw4RkV5WVNna25GcFpWQ0tLWkJfRGktRkFDZzU0d0thVnRWNTZ1RUltdkM?oc=5","date":"2020-08-01","type":"pipeline","source":"Ophthalmology Times","summary":"Next frontier in glaucoma: Beyond IOP-lowering treatments - Ophthalmology Times","headline":"Next frontier in glaucoma: Beyond IOP-lowering treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWlVGUk45b0t1cWdnVlZhZTVHaE5ySHlKX0tnSEtmM0U4ZEFkdU1Rdjc0dUdXUnFBdHk0VVN3X1ppZmd0bHdvUy1SaHlQbmpHMms2NDB0ZWk1MnlYQmh1dDE2bDdRc2NWU2pMLUJZUm9RbUZFLVd0WUlyMlA5R09rMVZ4V3d3NGtWR2lPa0hpN21UM1NOOWRMdUEwUUdqd18yUjh3OFJrU3k?oc=5","date":"2020-01-08","type":"pipeline","source":"statnews.com","summary":"A new biotechnology and pharmaceutical industry commitment to patients and the public - statnews.com","headline":"A new biotechnology and pharmaceutical industry commitment to patients and the public","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNVkFQRW9wU0hOWVV6bUNSNkRETHBNZjdLZHZscnd6RlZGdmM5cThqTFJjRGNoOVdSYkZxRTNMRHBpRW15UE9RY2UweXdsQml6XzJvZFd3bWp4c1hXcXBDSWdSa0ppVmJUeUpYbjFJZ19nLTBuUWdtbUUwNEJfZk1zWHhaMGg5aTA5LXhYTldQMFA4aEdLN0RoYjJ5bU90WXZQQmc?oc=5","date":"2019-01-23","type":"pipeline","source":"New Haven Register","summary":"New Haven bio-tech company working on paralysis drug stymied by shutdown - New Haven Register","headline":"New Haven bio-tech company working on paralysis drug stymied by shutdown","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNQlZNeUZkVEMwdXNaRGFCdjBTekVOZTRJc1BUZ1RoODh0ZlZ3VzhSUllIS2dJQnB5VThUUzV4SUVXLWRvN20xcHVwYmJNbjc0bWg0LWV2NDdLU1V5Y2U2c3dNbWl4Si1lcHd4eTg1TDhvWjV6ZmM2TzgwektHZ0l1Vjh3ZEppb0hiS01QQWYxY0JGUzNjdTJoV1FtMjNaNDNXcWxVYUt3?oc=5","date":"2017-08-05","type":"pipeline","source":"New Haven Register","summary":"New Haven doctor works to repair central nervous system injuries - New Haven Register","headline":"New Haven doctor works to repair central nervous system injuries","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}